Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Completes 95 Percent of BioReliance Merger

NEW YORK, Feb. 6 (GenomeWeb News) - Invitrogen announced today that its subsidiary, Baseball Acquisition, has accepted for purchase about 95 percent of the outstanding shares of BioReliance, a Rockville, Md.-based contract service organization.


Invitrogen announced in  December that it would acquire the company for $500 million. The announcement today said that Invitrogen would pay $48 per share for BioReliance's approximately 8.4 million shares.


The acquiring company said further that it intends to effect a short-term merger now that 95 percent of the shares are to be purchased. Once the merger has been entirely completed, BioReliance will become a wholly-owned subsidiary of Invitrogen.


The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.